Back to Search
Start Over
PAD Inhibitors as a Potential Treatment for SARS-CoV-2 Immunothrombosis.
- Source :
-
Biomedicines [Biomedicines] 2021 Dec 09; Vol. 9 (12). Date of Electronic Publication: 2021 Dec 09. - Publication Year :
- 2021
-
Abstract
- Since the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, the virus's dynamicity has resulted in the evolution of various variants, including the delta variant and the more novel mu variant. With a multitude of mutant strains posing as challenges to vaccine efficacy, it is critical that researchers embrace the development of pharmacotherapeutics specific to SARS-CoV-2 pathophysiology. Neutrophil extracellular traps and their constituents, including citrullinated histones, display a linear connection with thrombotic manifestations in COVID-19 patients. Peptidylarginine deiminases (PADs) are a group of enzymes involved in the modification of histone arginine residues by citrullination, allowing for the formation of NETs. PAD inhibitors, specifically PAD-4 inhibitors, offer extensive pharmacotherapeutic potential across a broad range of inflammatory diseases such as COVID-19, through mediating NETs formation. Although numerous PAD-4 inhibitors exist, current literature has not explored the depth of utilizing these inhibitors clinically to treat thrombotic complications in COVID-19 patients. This review article offers the clinical significance of PAD-4 inhibitors in reducing thrombotic complications across various inflammatory disorders like COVID-19 and suggests that these inhibitors may be valuable in treating the origin of SARS-CoV-2 immunothrombosis.
Details
- Language :
- English
- ISSN :
- 2227-9059
- Volume :
- 9
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Biomedicines
- Publication Type :
- Academic Journal
- Accession number :
- 34944683
- Full Text :
- https://doi.org/10.3390/biomedicines9121867